环状RNA FLI1在肝细胞癌患者中的表达及其与预后的关系

唐凌; 邱露蝶; 秦文; 吴刚

doi:10.3969/j.issn.1001-5256.2019.09.019

环状RNA FLI1在肝细胞癌患者中的表达及其与预后的关系

DOI: 10.3969/j.issn.1001-5256.2019.09.019

1. 西南医科大学附属医院传染消化科
2. 西南医科大学附属医院中医科

基金项目:

四川省卫生厅基金资助(120326)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1305
- HTML全文浏览量: 65
- PDF下载量: 250
- 被引次数: 0
出版历程
- 收稿日期: 2019-05-13
- 出版日期: 2019-09-20

Expression of circular RNA FLI1 in patients with hepatocellular carcinoma and its association with prognosis

Department of Infectious Digestion, The Affiliated Hospital of Southwest Medical University

Research funding:

摘要

摘要: 目的探讨环状RNA FLI1（circ FLI1）在肝细胞癌（HCC）患者中的表达及意义。方法收集2013年1月-2018年1月于西南医科大学附属医院经手术切除的45例HCC患者的癌组织及配对癌旁组织和血清样本（HCC组）。同时收集45例健康体检者的血清标本（对照组）。人肝癌细胞株HepG2、SMMC7721、HB611均来自中国科学院生物化学与细胞生物学研究所。real-time PCR法检测circ FLI1在肝癌细胞及45例肝癌组织、血清标本中的表达。计量资料2组间比较采用t检验。采用Kaplan-Meier法分析circ FLI1表达与患者生存时间的关系,采用受试者工作特征曲线（ROC曲线）分析血清circ FLI1 E2-4及circ FLI1 E2-5作为诊断HCC生物标志物的潜能,应用单因素及多因素Cox比例风险模型分析影响HCC预后的因素。结果 circ FLI1 E2-5及circ FLI1 E2-4在3种肝癌细胞中高表达。circ FLI1 E2-4（7. 09±0. 26 vs 1. 14±0. 20,t=19. 970,P <0. 001）及circ FL...
- 癌,肝细胞 /
- 环状RNA FLI1 /
- 基因表达 /
- 预后
Abstract: Objective To investigate the expression and significance of circular RNA FLI1 ( circ FLI1) in patients with hepatocellular carcinoma ( HCC) . Methods A total of 45 HCC patients who underwent surgical resection in The Affiliated Hospital of Southwest Medical University from January 2013 to January 2018 were enrolled as HCC group, and the samples of cancerous tissue, adjacent tissue, and serum were collected. A total of 45 healthy individuals who underwent physical examination were enrolled as control group, and their serum samples were collected. Human hepatoma cell lines HepG2, SMMC7721, and HB611 were obtained from Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences. qRT-PCR was used to measure the expression of circ FLI1 in hepatoma cells and 45 samples of cancerous tissue and serum. The t-test was used for comparison of continuous data between groups. The Kaplan-Meier method was used to analyze the association between circ FLI1 expression and survival time; the receiver operating characteristic ( ROC) curve was used to evaluate the potential of serum circ FLI1 E2-4 and circ FLI1 E2-5 as the biomarkers for the diagnosis of HCC; univariate and multivariate Cox proportional hazards model analyses were used to investigate the influencing factors for the prognosis of HCC. Results There was high expression of circ FLI1 E2-5 and circ FLI1 E2-4 in the three hepatoma cell lines. Compared with the control group, the HCC group had sig-nificantly higher serum levels of circ FLI1 E2-4 ( 7. 09 ± 0. 26 vs 1. 14 ± 0. 20, t = 19. 970, P < 0. 001) and circ FLI1 E2-5 ( 7. 50 ±0. 25 vs 1. 29 ± 0. 30, t = 16. 640, P < 0. 001) . For the HCC patients, the expression of circ FLI1 E2-4 and circ FLI1 E2-5 in cancerous tissue was significantly higher than that in adjacent tissue ( circ FLI1 E2-4: 7. 62 ± 1. 33 vs 1. 55 ± 0. 32, t = 15. 560, P < 0. 001; circ FLI1 E2-5: 7. 92 ± 0. 35 vs 1. 42 ± 0. 39, t = 21. 170, P < 0. 001) . The patients with high expression of circ FLI1 E2-5 had significantly shorter median progression-free survival time and overall survival time than those with low expression ( median progression-free survival time: 11. 17 ± 0. 49 months vs 23. 35 ± 1. 27 months, χ2= 28. 480, P < 0. 001; overall survival time: 19. 75 ± 0. 76 months vs 37. 44 ± 1. 57 months, χ2= 21. 750, P < 0. 001) . The patients with high expression of circ FLI1 E2-4 had significantly shorter median progression-free survival time and overall survival time than those with low expression ( median progression-free survival time: 10. 29 ± 0. 42 months vs 24.65 ± 1. 58 months, χ2= 19. 620, P < 0. 001; overall survival time: 21. 32 ± 0. 55 months vs 35. 69 ± 1. 74 months, χ2= 19. 730, P < 0.001) . As a serum marker for the diagnosis of HCC, serum circ FLI1 E2-4 had an area under the ROC curve of 0. 910 ( 95% confidence interval [CI]: 0. 621-0. 970, P < 0. 001) , with a sensitivity of 84. 3% and a specificity of 90. 5%. As a serum marker for the diagnosis of HCC, serum circ FLI1 E2-5 had an area under the ROC curve of 0. 760 ( 95% CI: 0. 650-0. 860, P < 0. 001) , with a sensitivity of80. 5% and a specificity of 87. 3%. The multivariate Cox proportional hazards model analysis showed that serum circ FLI1 E2-4 ( hazard ratio [HR]= 3. 060, 95% CI: 1. 630-5. 870, P < 0. 05) and circ FLI1 E2-5 ( HR = 2. 560, 95% CI: 1. 250-6. 460, P < 0. 05) were independent influencing factors for the prognosis of HCC patients. Conclusion Circ FLI1 is highly expressed in the tissue and serum of HCC patients, which is associated with the prognosis of patients. It may be a potential biomarker for prognosis and a therapeutic target for HCC.
- carcinoma, hepatocellular /
- circRNA FLI1 /
- gene expression /
- prognosis

HTML全文

参考文献(25)

[1] CHOWDHURY KD, SARKAR A, CHATTERJEE S, et al. Cathepsin B mediated scramblase activation triggers cytotoxicity and cell cycle arrest by andrographolide to overcome cellular resistance in cisplatin resistant human hepatocellular carcinoma HepG2 cells[J]. Environ Toxicol Pharmacol, 2019, 6 (8) :120-132.

[2] HWANG-BO H, LEE WS, NAGAPPAN A, et al. Morin enhances auranofin anticancer activity by up-regulation of DR4and DR5 and modulation of Bcl-2 through reactive oxygen species generation in Hep3B human hepatocellular carcinoma cells[J]. Phytother Res, 2019, 33 (5) :1384-1393.

[3] LONG J, WANG A, BAI Y, et al. Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma[J]. EBio Medicine, 2019, 42:363-374.

[4] CAI L, QI B, WU X, et al. Circular RNA Ttc3 regulates cardiac function after myocardial infarction by sponging miR-15b[J].J Mol Cell Cardiol, 2019, 130:10-22.

[5] CHEN T, LUO J, GU Y, et al. Comprehensive analysis of circular RNA profiling in AZD9291-resistant non-small cell lung cancer cell lines[J]. Thorac Cancer, 2019, 10 (4) :930-941.

[6] LI X, HE M, GUO J, et al. Upregulation of circular RNA circERBB2 predicts unfavorable prognosis and facilitates the progression of gastric cancer via miR-503/CACUL1 and miR-637/MMP-19 signaling[J]. Biochem Biophys Res Commun, 2019, 511 (4) :926-930.

[7] SONG H, XU D, SHI P, et al. Upregulated circ RNA hsa_circ_0000337 promotes cell proliferation, migration, and invasion of esophageal squamous cell carcinoma[J]. Cancer Manag Res, 2019, 11:1997-2006.

[8] JIAO X, SHU G, LIU H, et al. The diagnostic value of chemokine/chemokine receptor pairs in hepatocellular carcinoma and colorectal liver metastasis[J]. J Histochem Cytochem, 2019, 67 (5) :299-308.

[9] CHANG LEE R, TEBBUTT N. Systemic treatment of advanced hepatocellular cancer:New hope on the horizon[J]. Expert Rev Anticancer Ther, 2019, 19 (4) :343-353.

[10] ZHOU WP, YANG Y. Improving the standardized diagnosis level for primary liver cancer[J]. Chin J Dig Surg, 2018, 17 (5) :430-432. (in Chinese) 周伟平, 杨远.提高原发性肝癌的规范化诊断水平[J].中华消化外科杂志, 2018, 17 (5) :430-432.

[11] IMAI Y, YOSHIDA O, WATANABE T, et al. Stimulated hepatic stellate cell promotes progression of hepatocellular carcinoma due to protein kinase R activation[J]. PLo S One, 2019, 14 (2) :e0212589.

[12] BACH DH, LEE SK, AND SOOD AK. Circular RNAs in cancer[J]. Mol Ther Nucleic Acids, 2019, 16:118-129.

[13] PENG XD, FANG WJ, HE Y. Circular RNA:Function and role in colorectal cancer[J]. Chin J Clin Pharmacol Ther, 2017, 22 (10) :1189-1194. (in Chinese) 彭向东, 方伟进, 何阳.环状RNA的功能及在结直肠癌中的研究进展[J].中国临床药理学与治疗学, 2017, 22 (10) :1189-1194.

[14] SUN LF, ZHANG B, CHEN XJ, et al. Circular RNAs in human and vertebrate neural retinas[J]. RNA Biol, 2019, 16 (6) :821-829.

[15] SU Y, XU C, LIU Y, et al. Circular RNA hsa_circ_0001649 inhibits hepatocellular carcinoma progression via multiple miRNAs sponge[J]. Aging (Albany NY) , 2019, 11 (10) :3362-3375.

[16] YANG X, SONG H, ZI Z, et al. Circ_0005075 promotes hepatocellular carcinoma progression by suppression of microRNA-335[J]. J Cell Physiol, 2019.[Epub ahead of print]

[17] WANG ZY, ZHU Z, WANG HF, et al. Downregulation of circDYNC1H1 exhibits inhibitor effect on cell proliferation and migration in hepatocellular carcinoma through miR-140-5p[J]. J Cell Physiol, 2019, 234 (10) :17775-17785.

[18] XU L, FENG X, HAO X, et al. CircSETD3 (Hsa_circ_0000567) acts as a sponge for microRNA-421 inhibiting hepatocellular carcinoma growth[J]. J Exp Clin Cancer Res, 2019, 38 (1) :98.

[19] LI X, SHEN M. Circular RNA hsa_circ_103809 suppresses hepatocellular carcinoma proliferation and invasion by sponging miR-620[J]. Eur Rev Med Pharmacol Sci, 2019, 23 (2) :555-566.

[20] LI Z, ZHOU Y, YANG G, et al. Using circular RNA SMARCA5as a potential novel biomarker for hepatocellular carcinoma[J]. Clin Chim Acta, 2019, 492:37-44.

[21] CHEN N, ZHAO G, YAN X, et al. A novel FLI1 exonic circular RNA promotes metastasis in breast cancer by coordinately regulating TET1 and DNMT1[J]. Genome Biol, 2018, 19 (1) :218.

[22] HARLOW ML, CHASSE MH, BOGUSLAWSKI EA, et al. Trabectedin inhibits EWS-FLI1 and Evicts SWI/SNF from chromatin in a schedule dependent manner[J]. Clin Cancer Res, 2019, 25 (11) :3417-3429.

[23] PFALTZGRAFF ER, APFELBAUM A, KASSA AP, et al. Anatomic origin of osteochondrogenic progenitors impacts sensitivity to EWS-FLI1-induced transformation[J]. Cancers (Basel) , 2019, 11 (3) :313.

[24] CONRAD S, DEMURGER F, MORADKHANI K, et al. 11q24.2q24. 3 microdeletion in two families presenting features of Jacobsen syndrome, without intellectual disability:Role of FLI1, ETS1, and SENCR long noncoding RNA[J]. Am J Med Genet A, 2019, 179 (6) :993-1000.

[25] GIERISCH ME, PEDOT G, WALSER F, et al. USP19 deubiquitinates EWS-FLI1 to regulate Ewing sarcoma growth[J].Sci Rep, 2019, 9 (1) :951.

施引文献

资源附件(0)

访问统计